Open access
Open access
Powered by Google Translator Translator

Onco-hematology

RCT: In patients with previously untreated Diffuse Large B-Cell Lymphoma, a modified regimen of R-CHOP (pola-R-CHP), in which vincristine was replaced with polatuzumab, was associated with improved outcomes compared to standard R-CHOP treatment.

21 Jan, 2022 | 09:28h | UTC

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)

 


A single-arm study evaluated Naive T-Cell depleted peripheral blood stem-cell grafts for the prevention of chronic graft-versus-host disease.

19 Jan, 2022 | 08:22h | UTC

Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease – Journal of Clinical Oncology

Commentary: New graft strategy may improve outcomes for blood stem cell recipients – University of Pittsburg

 


Prolonged follow-up of RCT: Emission Tomography–driven strategy in advanced Hodgkin Lymphoma.

19 Jan, 2022 | 08:16h | UTC

Positron Emission Tomography–Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study – Journal of Clinical Oncology (link to abstract – $ for full-text)

 


RCT: Sirolimus plus prednisolone vs. sirolimus monotherapy for kaposiform hemangioendothelioma.

18 Jan, 2022 | 09:08h | UTC

Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial – Blood (link to abstract – $ for full-text)

 


Best Practice Recommendations: Management of adults and children receiving CAR T-cell therapy.

12 Jan, 2022 | 08:31h | UTC

Management of Adults and Children receiving CAR T-cell therapy: 2021 Best Practice Recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA) – Annals of Oncology

 


Hematology, the ASH Education Program – series of review articles with clinical cases published annually by the American Society of Hematology.

13 Dec, 2021 | 08:45h | UTC

Homepage: Hematology, the ASH Education Program

 


Non-inferiority randomized trial showed radiotherapy can be safely omitted in many children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma.

10 Dec, 2021 | 10:04h | UTC

Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial – The Lancet Oncology

 


RCT: Maribavir for refractory Cytomegalovirus infections with or without resistance post-transplant.

7 Dec, 2021 | 08:37h | UTC

Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results from a Phase 3 Randomized Clinical Trial – Clinical Infectious Diseases

 


Review: Castleman disease.

26 Nov, 2021 | 09:49h | UTC

Castleman disease – Nature Reviews Disease Primers (if the link is paywalled, try this one)

Infographic: Castleman Disease (if the link is paywalled, try this one)

 


Assessment of arsenic trioxide and all-trans retinoic acid for the treatment of pediatric acute promyelocytic leukemia.

14 Nov, 2021 | 19:32h | UTC

Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children’s Oncology Group AAML1331 Trial – JAMA Oncology

News release: Drug combination helps children with acute promyelocytic leukemia avoid conventional chemotherapy – NIH News Releases

 

Commentary on Twitter

 


Cluster RCT: In older adults with advanced cancer, a geriatric assessment program reduced the toxic effects of cancer treatment.

5 Nov, 2021 | 09:48h | UTC

Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study – The Lancet

News Release: Less Chemotherapy, Personalized Care: Wilmot Study Reinforces Major Strides in Geriatric Oncology – University of Rochester Medical Center

Related:

RCT: A geriatric assessment–driven intervention can reduce chemotherapy-related toxic effects in older adults with cancer.

Perspective: A Cancer Care Approach Tailored to The Elderly May Have Better Results

 

Commentary from the author on Twitter (thread – click for more)

 


CDC Guidance: Immunocompromised may need a fourth Covid-19 shot.

4 Nov, 2021 | 10:06h | UTC

Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States – Centers for Disease Control and Prevention

Commentaries:

Immunocompromised may need a fourth Covid-19 shot, CDC says – CNN

Some immunocompromised people can receive a 4th Covid shot, CDC says – NBC News

 


ASCO Guideline Update: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy.

2 Nov, 2021 | 02:51h | UTC

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update – Journal of Clinical Oncology

 


ASCO Guideline: Management of immune-related adverse events in patients treated with Chimeric Antigen Receptor T-Cell Therapy.

2 Nov, 2021 | 02:47h | UTC

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline – Journal of Clinical Oncology

 


RCT: Daratumumab, lenalidomide, and dexamethasone vs. lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma.

28 Oct, 2021 | 09:53h | UTC

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial – The Lancet Oncology

Commentary: Overall Survival in the MAIA Trial: Daratumumab, Lenalidomide, and Dexamethasone for Newly Diagnosed Transplant-Ineligible Patients With Multiple Myeloma – The ASCO Post

 


NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.

21 Oct, 2021 | 10:06h | UTC

Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology – Journal of the National Comprehensive Cancer Network

Related:

ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer

Review: venous and arterial thromboembolism in patients with cancer.

Systematic Review: Does testing for cancer in people with unprovoked blood clots in the legs and lungs reduce cancer- and blood clot-related death and illness?

M-A: Extended thromboprophylaxis after hospital discharge for medically ill patients with cancer – Extended thromboprophylaxis is not associated with a reduced rate of venous thromboembolic events and is associated with increased risk of hemorrhage

Systematic review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy

 


Systematic Review: Direct oral anticoagulants (DOACs) may be beneficial for people being treated for cancer who have no therapeutic or prophylactic indication for anticoagulation.

14 Oct, 2021 | 09:44h | UTC

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation – Cochrane Library

 


State of the Art Review: Advances in acute myeloid leukemia.

8 Oct, 2021 | 10:05h | UTC

Advances in acute myeloid leukemia – The BMJ

 

Commentary on Twitter

 


Series from the Lancet journals: Hematological malignancies in older people.

6 Oct, 2021 | 08:47h | UTC

Homepage: Haematological malignancies in older people – The Lancet Haematology

Commentary: Living longer and better with haematological malignancies: a promise for older adults too? (free registration required)

A comprehensive approach to therapy of haematological malignancies in older patients (free registration required)

Frailty assessment in the care of older people with haematological malignancies

Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care (free registration required)

Palliative care of patients with haematological malignancies: strategies to overcome difficulties via integrated care

Implementation of geriatric haematology programmes for the treatment of older people with haematological malignancies in low-resource settings

 


Podcast: Neutropenic Fever.

28 Sep, 2021 | 08:52h | UTC

#288 LIVE! Neutropenic Fever featuring Dr. Susan Seo – The Curbsiders

 


Guideline: Acute abdomen in the immunocompromised patient.

16 Aug, 2021 | 01:00h | UTC

Acute abdomen in the immunocompromised patient: WSES, SIS-E, WSIS, AAST, and GAIS guidelines – World Journal of Emergency Surgery

 


Antibody response to COVID-19 vaccination in adults with hematologic malignant disease.

13 Aug, 2021 | 09:47h | UTC

Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease – JAMA Oncology

 

Commentary on Twitter

 


Guideline: Laboratory detection and initial diagnosis of monoclonal gammopathies.

6 Aug, 2021 | 09:56h | UTC

Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies: Guideline From the College of American Pathologists in Collaboration With the American Association for Clinical Chemistry and the American Society for Clinical Pathology – Archives of Pathology & Laboratory Medicine

 


European PanCare Follow Up Recommendations for surveillance of late effects of childhood, adolescent, and young adult cancer.

1 Aug, 2021 | 23:59h | UTC

European PanCare Follow Up Recommendations for surveillance of late effects of childhood, adolescent, and young adult cancer – European Journal of Cancer

 


Survival outcomes for cancer types with the highest death rates for adolescents and young adults, 1975-2016.

1 Aug, 2021 | 23:58h | UTC

Survival outcomes for cancer types with the highest death rates for adolescents and young adults, 1975-2016 – Cancer

Commentary: Survival Trends for Adolescents and Young Adults With Cancer: 40-Year Analysis – The ASCO Post

 


Stay Updated in Your Specialty

No spam, just news.